Search by Drug Name or NDC
NDC 62856-0455-10 DAYVIGO 5 mg/1 Details
DAYVIGO 5 mg/1
DAYVIGO is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eisai Inc.. The primary component is LEMBOREXANT.
MedlinePlus Drug Summary
Lemborexant is used to treat insomnia (difficulty falling asleep or staying asleep). Lemborexant belongs to a class of medications called hypnotics. It works by slowing activity in the brain to allow sleep.
Related Packages: 62856-0455-10Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Lemborexant
Product Information
| NDC | 62856-0455 |
|---|---|
| Product ID | 62856-455_c4274f49-6deb-4d9a-bd64-21728c025394 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | DAYVIGO |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | lemborexant |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 5 |
| Active Ingredient Units | mg/1 |
| Substance Name | LEMBOREXANT |
| Labeler Name | Eisai Inc. |
| Pharmaceutical Class | Cytochrome P450 2B6 Inducers [MoA], Orexin Receptor Antagonist [EPC], Orexin Receptor Antagonists [MoA] |
| DEA Schedule | CIV |
| Marketing Category | NDA |
| Application Number | NDA212028 |
| Listing Certified Through | 2023-12-31 |
Package
NDC 62856-0455-10 (62856045510)
| NDC Package Code | 62856-455-10 |
|---|---|
| Billing NDC | 62856045510 |
| Package | 5 CARTON in 1 TRAY (62856-455-10) / 1 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK |
| Marketing Start Date | 2020-04-07 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |